MAPT and Alzheimer disease: Recent studies have indicated that AChE inhibitors could also reduce the aggregation of tau proteins in the regions of the entorhinal cortex and hippocampus in amyloid-positive participants, which may exhibit some neuroprotective effects in patients within the AD continuum (Yasuno and Minami 2021).